Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded at Wall Street Zen

Key Points

• Fresenius Medical Care AG & Co. KGaA was upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen, while other brokerages have varying ratings affecting market perception.
• The company reported earnings of $0.52 per share, beating analysts' expectations, and generated revenues of $5.54 billion in its last quarter.
• Fresenius Medical Care's stock has experienced a 12-month price range between $18.94 and $30.46, currently trading around $27.29, with an average rating of "Hold."

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

A number of other brokerages have also commented on FMS. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating in a report on Wednesday, October 15th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Morgan Stanley reaffirmed an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Finally, UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a "sell" rating to an "underperform" rating in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has an average rating of "Hold" and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Trading Up 1.4%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $27.29 on Friday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.94 and a 12-month high of $30.46. The stock has a market cap of $16.01 billion, a P/E ratio of 22.36, a P/E/G ratio of 0.64 and a beta of 0.92. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. The business's 50 day moving average is $25.88 and its 200-day moving average is $26.41.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The company had revenue of $5.54 billion for the quarter, compared to analysts' expectations of $5 billion. Equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 34.0% in the first quarter. GAMMA Investing LLC now owns 9,603 shares of the company's stock worth $239,000 after purchasing an additional 2,439 shares in the last quarter. Spire Wealth Management bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 1st quarter valued at about $27,000. Wayfinding Financial LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter worth approximately $25,000. Callan Capital LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 6.6% during the 1st quarter. Callan Capital LLC now owns 13,974 shares of the company's stock valued at $348,000 after buying an additional 870 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 0.9% in the 1st quarter. Crossmark Global Holdings Inc. now owns 64,871 shares of the company's stock worth $1,615,000 after purchasing an additional 584 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.